SCHEMBL14780241

SCHEMBL14780241

COc1nc2ncnc(NCc3ccccc3)c2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.65
EGFR P00533 10/20 0.58
LMNA P02545 3/20 0.56
TSHR P16473 3/20 0.56
MAPK1 P28482 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
CDK2 P24941 1/20 0.56
PI4KA P42356 2/20 0.54
PI4K2B Q8TCG2 2/20 0.54
PI4K2A Q9BTU6 2/20 0.54
PI4KB Q9UBF8 2/20 0.54
KDM4E B2RXH2 2/20 0.49
MAPT P10636 1/20 0.49
OXTR P30559 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
LCK P06239 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8009111 0.84 CSF1R (0.71) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14780240 0.83 EGFR (0.52) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14778603 0.83 CSF1R (0.70) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14778797 0.81 CSF1R (0.71) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14778104 0.81 SMN1; SMN2 (0.60) LMNATSHRMAPK1CYP1A2CYP2D6
SCHEMBL14780086 0.80 CSF1R (0.70) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14779314 0.80 CSF1R (0.70) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14779414 0.80 CSF1R (0.70) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14779730 0.80 CSF1R (0.65) CSF1REGFRLMNATSHRMAPK1
SCHEMBL14778707 0.80 CSF1R (0.69) CSF1REGFRLMNATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2755977-B1 6,8-DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE Univerzita Palackého v Olomouci (CZ) 2016-11-02 EP disclosed
EP-2755977-A1 6, 8- DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE Univerzita Palackého v Olomouci (CZ) 2014-07-23 EP disclosed
US-20130072506-A1 6,8-DISUBSTITUTED PURINE COMPOSITIONS ZAHAJSKA LENKA (CZ) 2013-03-21 US disclosed
WO-2013037333-A1 6, 8- DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2013-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072506-A1 6,8-DISUBSTITUTED PURINE COMPOSITIONS UNG, PNP, UMPS CSF1R 2693/4885EGFR 3460/4885LMNA 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.